Editor’s Note September 19, 2011
OneMedSentinel is pleased to bring you another round of stories and interviews with some of the most promising companies and technologies, as well as innovative […]
News
ImmunoGenetix Discovers a Safer Approach To HIV Treatment
James Laufenberg, CEO of ImmunoGenetix was interviewed by OneMedRadio where he discussed a therapeutic DNA based composition to treat HIV, GenePro.
This Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his new column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Advaxis CEO Tom Moore Discovers A New Way To Fight Cancer
OneMedRadio interviewed Tom Moore, CEO and Chairman of the Board of Directors of Advaxis [OTC:ADXS]. He discusses the company’s novel immunotherapy technology.
Editor’s Note September 12, 2011
The weather is cooling, but the health industry is heatings things up. OneMedSentinel is pleased to bring you another round of stories and interviews with […]
The Week In Diagnostics
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business. Peter has over 30 years experience as a scientist, science journalist, and publisher.
AdvaMed 2011 Featuring Over 70 Company Presentations
The conference will feature over 70 company presentations. Below are some interesting technologies attendees can expect to hear from.
Protected: VIDEO: Investment Opportunities in Greater Zurich Area
There is no excerpt because this is a protected post.
Editor’s Note September 6, 2011
OneMedSentinel continues coverage of some of the most promising companies and technologies, as well as innovative approaches to funding the growth economy. In this issue: […]
David Strupp Discusses Rodman and Renshaw One Of The Largest Investment Conferences Worldwide
Considered to be bankers for the growth industry, Rodman and Renshaw goes beyond the life science industries.